Modus Therapeutics Holding AB (MODTX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.552x

Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million ≈ $-538.40K USD) by net assets (Skr9.07 Million ≈ $976.18K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Modus Therapeutics Holding AB market cap and net worth for the company's overall valuation and market capitalisation.

Modus Therapeutics Holding AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency. See debt repayment capacity of Modus Therapeutics Holding AB to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Accuracy Shipping Limited NSE:ACCURACY	0.085x
Ace Oldfields PT JK:KUAS	0.002x
Aterian Inc NASDAQ:ATER	-0.069x
Mathios Refractories S.A. AT:MATHIO	0.009x
ZINC of Ireland NL AU:ZMI	-0.016x
Alchemy Resources Ltd AU:ALY	-0.023x
Abrdn Asia Focus PLC LSE:AAS	0.004x
Henderson European Focus Trust Plc LSE:HET	0.006x

Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. View MODTX stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr9.07 Million ≈ $976.18K	Skr-18.07 Million ≈ $-1.95 Million	-1.993x	+71.00%
2024-12-31	Skr2.14 Million ≈ $229.98K	Skr-14.68 Million ≈ $-1.58 Million	-6.870x	-628.09%
2023-12-31	Skr17.68 Million ≈ $1.90 Million	Skr-16.68 Million ≈ $-1.80 Million	-0.944x	-111.23%
2022-12-31	Skr-2.58 Million ≈ $-278.19K	Skr-21.72 Million ≈ $-2.34 Million	8.404x	+922.46%
2021-12-31	Skr15.73 Million ≈ $1.69 Million	Skr-16.08 Million ≈ $-1.73 Million	-1.022x	+1.16%
2020-12-31	Skr7.00 Million ≈ $752.77K	Skr-7.23 Million ≈ $-778.17K	-1.034x	-106.33%
2019-12-31	Skr-2.69 Million ≈ $-289.06K	Skr-43.90 Million ≈ $-4.72 Million	16.343x	+1075.08%
2018-12-31	Skr23.90 Million ≈ $2.57 Million	Skr-40.06 Million ≈ $-4.31 Million	-1.676x	--

About Modus Therapeutics Holding AB

ST:MODTX Sweden Biotechnology

Market Cap

$7.57 Million

Skr70.31 Million SEK

Market Cap Rank

#27822 Global

#607 in Sweden

Share Price

Skr0.40

Change (1 day)

+2.56%

52-Week Range

Skr0.27 - Skr0.54

All Time High

Skr6.80